Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Antimetastasis data to be presented by Chemokine at meeting
March 23rd, 2006
Chemokine Therapeutics Corp. (CHKT), a biotechnology company developing drugs in the field of chemokines, announced that the 97th annual meeting of the American Association for Cancer Research (AACR) in 2006 has accepted the results of the research study of Chemokine Therapeutics' anticancer compound, CTCE-9908, in a model of prostate cancer for presentation. The presentation, entitled "A peptide antagonist of chemokine receptor CXCR4 reduces tumor metastasis in a murine orthotopic model of human prostate cancer," will be presented on April 3, 2006 in Washington, DC. The study previously announced by the company demonstrated CTCE-9908 prevented the...
Source: Women's Health Weekly (2006-03-23)
|
